ClinicalTrials.gg
Not yet recruitingNCT07929155PROTECT-10Updated Nov 10, 2026

Influence of Neuromuscular Fatigue Accumulated During Training on Subsequent Chronic Adaptations: PROTECT-10

An interventional study of Trainig sessions in Healhty, sponsored by Centre Paul Strauss. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Centre Paul Strauss · Not applicable, Interventional, and Other

Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A 13-week longitudinal experimental study designed to determine how the level of neuromuscular fatigue induced by strength training influences chronic adaptations. Four assessment periods (pre-protocol, mid-point 1, mid-point 2, and post-protocol) will be used to measure neuromuscular, physiological, and structural parameters. A reference group will be included to assess measurement variability across the evaluation phases (this group will only undergo these assessments), while an experimental group will follow a standardized training protocol (in addition to the assessment phases).

Read the detailed description

Physical training is based on the dose-response principle, whereby the applied load determines the resulting adaptations. However, a higher dose does not consistently lead to greater gains (Hass et al., 2000; Mitchell et al., 2012), and the precise role of neuromuscular fatigue in chronic adaptations remains a subject of debate. Some studies suggest that fatigue-specifically peripheral fatigue, which directly reflects metabolic disturbances within the muscle-serves as a key stimulus for promoting neuromuscular adaptations (Rooney et al., 1994), while others have observed no significant effect (Folland et al., 2002). These discrepancies can be attributed to several factors: the lack of precise quantification of fatigue; the failure to distinguish between central and peripheral fatigue (the latter being a critical factor) (Hureau et al., 2022); and the failure to account for differences in fatigability between men and women (Hunter, 2016). Furthermore, recent research indicates that peripheral fatigue is regulated at an individual threshold by the tone of type III-IV muscle afferents, which modulate the central motor drive to limit the accumulation of fatigue (Amann et al., 2015; Hureau et al., 2016). Gaining a better understanding of how this threshold-along with its sensitivity and potential plasticity through training-influences the adaptive response is essential for optimizing exercise prescription, both for performance and for health.

02

Conditions studied

  • Healhty
03

In context

Lead sponsor

Centre Paul Strauss is the lead sponsor of 31 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman between 18 and 45 years of age
  • Active lifestyle (assessed via the GPAQ-2 questionnaire, with a minimum threshold defined as 600 MET-minutes per week)
  • Capable of understanding the objectives and risks associated with the research and providing -dated and signed-in the judgment of the investigator
  • Affiliated with a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Known neurological, neuromuscular, cardiovascular, respiratory, or psychiatric condition
  • Minors, adults under legal protection, or individuals unable to provide personally; high-level athletes or those undergoing strength-based training
  • Pregnant or breastfeeding women
  • Individuals in an emergency situation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • No intervention
    Reference

    This group will undergo only the assessment periods, without participating in the training program. It will allow for the monitoring of variations related to the passage of time, the repetition of tests, and measurement variability. This group will thus serve as a reference, and its results will be compared with those of the experimental group in order to estimate the actual effects of the training and to distinguish between "responders" and "non-responders" (Padilla et al., 2020; Bossi \& Mata, 2025).

  • Experimental
    experimental

    This group will benefit from training sessions in addition to assessments.

    Other: Trainig sessions

Interventions

  • OtherTrainig sessions

    3 training periods, each consisting of two training sessions per week.

06

What researchers measure

Primary outcomes

  1. maximal isometric strength

    Determine the change in the maximal isometric strength of the right knee extensors following the entire training program.

    Time frame: 3 weeks after the intervention

07

Study locations

1 site
  • CEERIPE
    Strasbourg, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 10, 2026
StartEst.
Nov 3, 2026
Primary completionEst.
May 3, 2028
CompletionEst.
May 3, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07929155
Lead sponsor
Centre Paul Strauss
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Nov 3, 2026 (estimated)
Primary completion
May 3, 2028 (estimated)
Completion
May 3, 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion